Anji Pharmaceuticals

Overview

Anji Pharmaceuticals is a clinical-stage biotechnology company developing innovative therapies targeting the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) and related inflammatory pathways. Founded in 2016, the company has a unique approach that combines expertise in metabolic disease and neuroinflammation, with a particular focus on [Parkinson's disease](/diseases/parkinsons-disease) where metabolic dysfunction and inflammation intersect.

Company Profile

| Attribute | Value |
|-----------|-------|
| Founded | 2016 |
| Headquarters | South San Francisco, California, USA |
| CEO | Dr. Raymond L. Hill |
| Funding | Series C ($85M, 2023) |
| Focus | NLRP3 inhibitors, metabolic inflammation |
| Stage | Phase 1/Preclinical |

Company History

Anji Pharmaceuticals was founded based on research from Stanford University and the University of Cambridge:

• Scientific founders: Dr. Qinghan Wang (Cambridge), Dr. Michael H. Chen (Stanford)
• Initial focus: Metabolic inflammation (NLRP3 in diabetes and obesity)
• Expansion: 2021 - Added neurodegenerative disease programs

The company's name "Anji" reflects its mission to bring "calm" (anji in Chinese) to dysregulated immune responses.

Science and Technology

Dual-Target Platform

Anji's platform targets both:

Metabolic inflammation: NLRP3 in metabolic disorders

Neuroinflammation: NLRP3 in neurodegenerative diseases

This dual focus provides unique insights into the relationship between systemic inflammation and brain inflammation.

Mechanism in Parkinson's Disease

...

Overview

Anji Pharmaceuticals is a clinical-stage biotechnology company developing innovative therapies targeting the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) and related inflammatory pathways. Founded in 2016, the company has a unique approach that combines expertise in metabolic disease and neuroinflammation, with a particular focus on [Parkinson's disease](/diseases/parkinsons-disease) where metabolic dysfunction and inflammation intersect.

Company Profile

| Attribute | Value |
|-----------|-------|
| Founded | 2016 |
| Headquarters | South San Francisco, California, USA |
| CEO | Dr. Raymond L. Hill |
| Funding | Series C ($85M, 2023) |
| Focus | NLRP3 inhibitors, metabolic inflammation |
| Stage | Phase 1/Preclinical |

Company History

Anji Pharmaceuticals was founded based on research from Stanford University and the University of Cambridge:

• Scientific founders: Dr. Qinghan Wang (Cambridge), Dr. Michael H. Chen (Stanford)
• Initial focus: Metabolic inflammation (NLRP3 in diabetes and obesity)
• Expansion: 2021 - Added neurodegenerative disease programs

The company's name "Anji" reflects its mission to bring "calm" (anji in Chinese) to dysregulated immune responses.

Science and Technology

Dual-Target Platform

Anji's platform targets both:

Metabolic inflammation: NLRP3 in metabolic disorders

Neuroinflammation: NLRP3 in neurodegenerative diseases

This dual focus provides unique insights into the relationship between systemic inflammation and brain inflammation.

Mechanism in Parkinson's Disease

Anji's approach recognizes the connection between metabolic dysfunction and PD:

• Metabolic link: Type 2 diabetes increases PD risk 2-3x
• Shared pathway: NLRP3 activated by both metabolic stress and alpha-synuclein
• Therapeutic angle: Block common inflammatory pathway

Pipeline

Programs

| Program | Mechanism | Indication | Stage | Status |
|---------|-----------|------------|-------|--------|
| ANJ-905 | NLRP3 inhibitor | Parkinson's disease | Preclinical | IND-enabling |
| ANJ-750 | NLRP3 inhibitor | Type 2 diabetes | Phase 1b | Completed |
| ANJ-802 | NLRP3/TNFR dual | Inflammatory diseases | Discovery | Early stage |
| ANJ-950 | NLRP3/LRRK2 dual | Parkinson's disease | Discovery | Lead optimization |

ANJ-905 (Parkinson's Disease)

ANJ-905 is Anji's lead Parkinson's disease program:

• Mechanism: Direct NLRP3 inhibition (NACHT domain)
• BBB penetration: Designed for CNS exposure
• Synergy: Potential combination with LRRK2 inhibitors

The program leverages learnings from ANJ-750 (diabetes) to optimize for CNS applications.

ANJ-950 (Dual-Target PD)

ANJ-950 represents Anji's innovative dual-target approach:

• Rationale: NLRP3 inflammation + LRRK2 dysfunction both drive PD
• Mechanism: Single molecule inhibiting both targets
• Advantage: Simplified regimen, potential enhanced efficacy

This program is in early discovery but represents a novel approach in the PD pipeline.

Clinical Data from ANJ-750

ANJ-750 (diabetes) has generated valuable human data:

• Phase 1a: Single ascending dose - safe, well-tolerated
• Phase 1b: 28-day multiple dose - reduced inflammatory biomarkers
• Key findings:
• 40% reduction in IL-1β after 28 days
• Improved insulin sensitivity
• No serious adverse events

This human data supports the rationale for NLRP3 inhibition in neuroinflammation.

Research Collaborations

Anji has established key partnerships:

• Stanford University: Metabolic inflammation research
• University of Cambridge: NLRP3 structural biology
• Michael J. Fox Foundation: PD biomarker development

Funding

| Round | Amount | Year | Investors |
|-------|--------|------|-----------|
| Series A | $20M | 2016 | Versant Ventures, Third Rock |
| Series B | $40M | 2019 | Google Ventures, Pfizer Ventures |
| Series C | $85M | 2023 | Andreessen Horowitz, RA Capital |

Competitive Position

Anji occupies a unique position with metabolic + CNS expertise:

| Company | Focus | Anji Differentiation |
|---------|-------|----------------------|
| Anji | Metabolic + CNS | Unique dual-expertise |
| Olacteant | Clinical data | Diabetes focus |
| NodThera | CNS only | Less metabolic expertise |
| Inception | CNS only | Earlier stage |

Development Timeline

Market Opportunity

Anji's metabolic-to-CNS approach addresses a significant unmet need:

| Parameter | Value |
|-----------|-------|
| PD patients with metabolic dysfunction | ~40% |
| Addressable market | $5-10B annually |
| Competitive advantage | Human data available |

References

[Anji Pharmaceuticals](https://www.anjipharma.com)

[Ogando J et al., Dapansutrile clinical data (2020)](https://pubmed.ncbi.nlm.nih.gov/32102873/)

See Also

• [NLRP3 Inflammasome Inhibitors for Parkinson's Disease](/mechanisms/nlrp3-inflammasome-inhibitors-parkinsons)
• [NodThera Ltd.](/companies/nodthera)
• [GLP-1 Receptor Agonists for PD](/companies/pd-glp-1-receptor-agonist-companies)
• [NLRP3 Inhibitors Investment Landscape](/investment/nlrp3-inflammasome)

Pathway Diagram

The following diagram shows the key molecular relationships involving Anji Pharmaceuticals discovered through SciDEX knowledge graph analysis: